By Jennifer Chiou
New York, Nov. 3 - Luminetx Corp. said it obtained $15 million in financing from investors, who included selected strategic investors and existing shareholders.
Proceeds will go toward additional capital for the ramp up of sales and marketing activities for its premier product, VeinViewer, a vascular imaging system, and to provide additional resources for the company's research and development and international sales efforts.
The Memphis biotechnology company also said it received clearance from the FDA for VeinViewer as a class 1 exempt medical device - thus beginning full commercial roll-out.
On Nov. 4, 2005, the company secured $11 million in series A preferred stock.
| Issuer: | Luminetx Corp.
|
| Issue: | Preferred stock
|
| Amount: | $15 million
|
| Investors: | Select strategic investors, existing shareholders
|
| Announcement date: | Nov. 3
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
